深圳市亦诺微医药科技有限公司 Immvira Co. Ltd
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China 2021-06-12 11:16
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021 2021-06-02 16:14
AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration 2021-04-20 08:30
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting 2021-04-08 20:47
ImmVira Announces Series C Financing with Leading Specialist Investors 2020-12-31 19:29
ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital 2020-09-24 00:09
ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies 2020-08-06 23:49
Immvira Announces the Appointment of Carl Yeung as Chief Financial Officer 2020-07-01 08:30
1 2